| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 1 Results |
| Timing: | Q4 2016 |
| Designation(s): | None |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Oncology |
| Indication: | Pancreatic Cancer |
| Lead Indication?: | Yes |
| Treatment Name: | MVT-5873 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | MabVax Therapeutics |
| Stock Symbol: | MBVX |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://www.mabvax.com/resources/Shareholder%20Letter%20September%202016.pdf |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuoteWe have stated that in the third quarter we will be providing a progress report on the clinical programs and announcing interim results from the Phase 1 clinical trial for our clinical development product MVT-5873 for the treatment of pancreatic cancer before the end of the year. We are highly encouraged by the progress thus far and anticipate very meaningful results to be disclosed in this timeframe.